Literature DB >> 12098064

Number of viable CD34(+) cells reinfused predicts engraftment in autologous hematopoietic stem cell transplantation.

D S Allan1, M Keeney, K Howson-Jan, J Popma, K Weir, M Bhatia, D R Sutherland, I H Chin-Yee.   

Abstract

Reduced CD34(+) cell viability due to cryopreservation has unknown effects on subsequent hematopoietic engraftment in autologous transplantation. Thirty-six consecutive autologous peripheral stem cell collections were analyzed for absolute viable CD34(+) cell numbers at the time of stem cell collection and prior to re-infusion. Viable CD34(+) cells were enumerated using single platform flow cytometry and the molecular exclusion dye 7-amino actinomycin D. The median number of viable CD34(+) cells was 3.6 x 10(6)/kg at the time of harvest and 2.0 x 10(6)/kg after thawing. When viable CD34(+)cells enumerated after thawing were <2.0, 2.0-5.0, or >5.0 x 10(6)/kg, the median time to platelet engraftment was 17, 12 and 10 days, respectively (P < 0.05 for comparison of the group with <2.0 x 10(6)/kg and the other two groups), and the median time to neutrophil engraftment was 13, 14 and 12 days, respectively (P = NS). A minimum of 2.0 x 10(6) CD34(+) cells/kg was harvested in 33 of 36 patients (92%) but only 19 of 36 (52%) patients met this threshold at the time of reinfusion. The reduced numbers of viable CD34(+) cells measured prior to re-infusion is associated with time to platelet engraftment and may be useful in monitoring stem cell loss during processing and identifying patients at risk of graft failure.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12098064     DOI: 10.1038/sj.bmt.1703575

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  23 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

2.  Quality of umbilical cord blood CD34+ cells in a double-compartment freezing bag cryopreserved without a rate-controlled programmed freezer.

Authors:  Masayoshi Minegishi; Tsuneo Itoh; Narumi Fukawa; Tamie Kitaura; Junko Miura; Hiroyuki Takahashi; Akira Suzuki; Yoshinori Kudo; Ayuko Narita; Yuko Sato; Masakuni Suzuki; Takanori Watanabe; Yuichi Wada; Yoichi Takeyama; Shigeru Tsuchiya
Journal:  Int J Hematol       Date:  2007-01       Impact factor: 2.490

Review 3.  Mobilized peripheral blood grafts include more than hematopoietic stem cells: the immunological perspective.

Authors:  F Saraceni; N Shem-Tov; A Olivieri; A Nagler
Journal:  Bone Marrow Transplant       Date:  2015-02-09       Impact factor: 5.483

4.  Quality assessment of umbilical cord blood units at the time of transplantation.

Authors:  Yoshinori Kudo; Masayoshi Minegishi; Osamu Seki; Hiroyuki Takahashi; Akira Suzuki; Ayuko Narita; Yuko Sato; Machiko Abe; Natsuko Ishioka; Hideo Harigae; Shigeru Tsuchiya
Journal:  Int J Hematol       Date:  2011-04-21       Impact factor: 2.490

5.  Infused neutrophil dose and haematopoietic recovery in patients undergoing autologous transplantation.

Authors:  L Bai; W Xia; K Wong; C Reid; C Ward; M Greenwood
Journal:  Bone Marrow Transplant       Date:  2014-02-24       Impact factor: 5.483

6.  Single Versus Dual Platform Analysis for Hematopoietic Stem Cell Enumeration Using ISHAGE Protocol.

Authors:  Rahul Naithani; Nitin Dayal; Gaurav Dixit
Journal:  Indian J Hematol Blood Transfus       Date:  2016-12-01       Impact factor: 0.900

7.  Collection and Processing of Mobilized Mouse Peripheral Blood at Lowered Oxygen Tension Yields Enhanced Numbers of Hematopoietic Stem Cells.

Authors:  Arafat Aljoufi; Scott Cooper; Hal E Broxmeyer
Journal:  Stem Cell Rev Rep       Date:  2020-10       Impact factor: 5.739

8.  Long-term follow up of patients proceeding to transplant using plerixafor mobilized stem cells and incidence of secondary myelodysplastic syndrome/AML.

Authors:  A Deol; J Abrams; A Masood; Z Al-Kadhimi; M H Abidi; L Ayash; L G Lum; V Ratanatharathorn; J P Uberti
Journal:  Bone Marrow Transplant       Date:  2013-03-11       Impact factor: 5.483

9.  Plerixafor and granulocyte colony-stimulating factor for first-line steady-state autologous peripheral blood stem cell mobilization in lymphoma and multiple myeloma: results of the prospective PREDICT trial.

Authors:  Nigel Russell; Kenny Douglas; Anthony D Ho; Mohamad Mohty; Kristina Carlson; G J Ossenkoppele; Giuseppe Milone; Macarena Ortiz Pareja; Daniel Shaheen; Arnold Willemsen; Nicky Whitaker; Christian Chabannon
Journal:  Haematologica       Date:  2012-09-14       Impact factor: 9.941

10.  High-Throughput Cell Concentration Using A Piezoelectric Pump in Closed-Loop Viscoelastic Microfluidics.

Authors:  Jeeyong Kim; Hyunjung Lim; Hyunseul Jee; Seunghee Choo; Minji Yang; Sungha Park; Kyounghwa Lee; Hyoungsook Park; Chaeseung Lim; Jeonghun Nam
Journal:  Micromachines (Basel)       Date:  2021-06-09       Impact factor: 2.891

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.